[Checkpoint inhibitors, the perspectives for elderly patients]
Related Experiment Video
Updated: Feb 22, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Thierry Landre1, Fatima Karaoud2, Cherifa Taleb2
1Service de Pharmacie, UCOG - Hôpital René Muret AP-HP, avenue du Dr Schaeffner, 93270 Sevran, France.
Abstract:
The arrival of new immunotherapies, called checkpoint inhibitors, is radically changing the world of oncology. Currently, there are some twenty different cancers which may respond to this type of therapy. It is therefore important that professionals involved in the care of elderly people with cancer are already made aware of these new treatments. This article explains how these checkpoint inhibitors work and describes their efficacy and their toxicity for elderly patients.
Related Concept Videos
Drug Dosing: Geriatric Patients
Pharmacodynamics in Geriatric Patients: Effects of Age
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption